Novartis' Zelnorm For Chronic Constipation Recommended With Restrictions
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients over the age of 65 and males should be excluded from treatment with Zelnorm (tegaserod) for chronic constipation, FDA gastrointestinal advisory committee says. Concerns about the risk of ischemic colitis and severe diarrhea, and lack of efficacy, in older patients were cited by committee members.
You may also be interested in...
Novartis' Zelnorm Approved For Chronic Constipation Without Gender Restrictions
FDA approves the supplemental indication despite an advisory committee recommendation that tegaserod use be limited to women. The agency follows the committee's recommendation on use only in individuals under age 65.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.